Perspectum Appoints Annalisa Jenkins, MBBS, FRCP to Board of Directors
Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians to more accurately diagnose and monitor patients with chronic metabolic diseases, multi-organ pathologies and cancer, announced the appointment of Annalisa Jenkins, MBBS, FRCP to its Board of Directors.
Dr. Jenkins brings extensive expertise in advancing biopharma programs from discovery to regulatory approval, which she gained during a distinguished industry career, including roles as the former head of Global R&D for Merck Serono and Head of Global Medical Affairs for Bristol Myers Squibb. Over her 20-year career, she has served as a chairwoman or director on the board of 14 public and private companies, including Oncimmune, a company focused on the diagnosis and treatment of cancer. Dr. Jenkins is the current chair of the court at the London School of Hygiene and Tropical Medicine, a co
University of Kentucky Johnson And Johnson Vaccine Pause spectrumnews1.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spectrumnews1.com Daily Mail and Mail on Sunday newspapers.
06 aprile 2021 13:40
Fonte: Adnkronos
#salute-e-benessere
-
BEIJING, and BRIDGEWATER, N.J., April 6, 2021 /PRNewswire/ Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma.
Glioma is a broad term describing neuroepithelial tumors originating from glial cells of the central nervous system, including astrocytic tumors such as glioblastomas (GBM). GBM is one of the most aggressive primary brain tumors and has median survival of 12 to 15 months, despite advances in surgery, chemotherapy, and radiation therapy1. Gan & Lee s current clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is investigating the treatment of advanced solid tumors which has the potential
Smart People: Dr Nick West
PharmaTimes
Abbott’s Dr Nick West talks to PharmaTimes about going beyond intervention to improve the care of cardiovascular patients in the UK
What is your current role and what does your day-to-day job involve?
I started as chief medical officer and divisional vice president of Global Medical Affairs within the Vascular division at Abbott in October 2019 after 20 years as a practising interventional cardiologist in the NHS. My day-to-day job is varied despite the pandemic and allows me to help shape our medical and scientific strategy as well as liaising with peers and colleagues around the world. The first months in the job involved a lot of travel to better understand the needs of our global customers and their patients, which is obviously no longer the case – but even now I can be in the Far East in the morning, Europe after that and finish up in the US in the afternoon/evening – even if only virtually!